These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Rationale for pertussis booster vaccination throughout life in Europe. Zepp F; Heininger U; Mertsola J; Bernatowska E; Guiso N; Roord J; Tozzi AE; Van Damme P Lancet Infect Dis; 2011 Jul; 11(7):557-70. PubMed ID: 21600850 [TBL] [Abstract][Full Text] [Related]
25. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age. Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247 [TBL] [Abstract][Full Text] [Related]
26. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection. Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126 [TBL] [Abstract][Full Text] [Related]
27. Duration of pertussis immunity after DTaP immunization: a meta-analysis. McGirr A; Fisman DN Pediatrics; 2015 Feb; 135(2):331-43. PubMed ID: 25560446 [TBL] [Abstract][Full Text] [Related]
28. Serologic response and antibody-titer decay in adults with pertussis. Heininger U; Cherry JD; Stehr K Clin Infect Dis; 2004 Feb; 38(4):591-4. PubMed ID: 14765356 [TBL] [Abstract][Full Text] [Related]
29. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough. Winsnes R; Lønnes T; Møgster B; Berdal BP Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124 [TBL] [Abstract][Full Text] [Related]
30. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. Le T; Cherry JD; Chang SJ; Knoll MD; Lee ML; Barenkamp S; Bernstein D; Edelman R; Edwards KM; Greenberg D; Keitel W; Treanor J; Ward JI; J Infect Dis; 2004 Aug; 190(3):535-44. PubMed ID: 15243929 [TBL] [Abstract][Full Text] [Related]
31. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Ahluwalia B; Moraes L; Magnusson MK; Öhman L Scand J Gastroenterol; 2018 Apr; 53(4):379-389. PubMed ID: 29523023 [TBL] [Abstract][Full Text] [Related]
32. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Mow WS; Abreu-Martin MT; Papadakis KA; Pitchon HE; Targan SR; Vasiliauskas EA Clin Gastroenterol Hepatol; 2004 Apr; 2(4):309-13. PubMed ID: 15067625 [TBL] [Abstract][Full Text] [Related]
33. Seroprevalence of IgG antibodies against Bordetella pertussis in healthy individuals aged 4-24 years in Turkey. Cevik M; Beyazova U; Aral AL; Duyan Camurdan A; Ozkan S; Sahin F; Aybay C Clin Microbiol Infect; 2008 Apr; 14(4):388-90. PubMed ID: 18190581 [TBL] [Abstract][Full Text] [Related]
35. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Esposito S; Agliardi T; Giammanco A; Faldella G; Cascio A; Bosis S; Friscia O; Clerici M; Principi N Infect Immun; 2001 Jul; 69(7):4516-20. PubMed ID: 11401994 [TBL] [Abstract][Full Text] [Related]
36. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Moses J; Alkhouri N; Shannon A; Raig K; Lopez R; Danziger-Isakov L; Feldstein AE; Zein NN; Wyllie R; Carter-Kent C Am J Gastroenterol; 2012 Jan; 107(1):133-8. PubMed ID: 21876562 [TBL] [Abstract][Full Text] [Related]
37. Pertussis outbreak in primary and secondary schools in Ludwigslust, Germany demonstrating the role of waning immunity. Sin MA; Zenke R; Rönckendorf R; Littmann M; Jorgensen P; Hellenbrand W Pediatr Infect Dis J; 2009 Mar; 28(3):242-4. PubMed ID: 19209094 [TBL] [Abstract][Full Text] [Related]
38. Antibody levels to Bordetella pertussis and Neisseria meningitidis in immunodeficient patients receiving immunoglobulin replacement therapy. Adam E; Church JA J Clin Immunol; 2015 Feb; 35(2):213-7. PubMed ID: 25631528 [TBL] [Abstract][Full Text] [Related]
39. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age. Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640 [TBL] [Abstract][Full Text] [Related]
40. Mouse and pig models for studies of natural and vaccine-induced immunity to Bordetella pertussis. Mills KH; Gerdts V J Infect Dis; 2014 Apr; 209 Suppl 1():S16-9. PubMed ID: 24626866 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]